PDL BioPharma (PDLI) Tops Q4 EPS by 12c, Beats on Revenues

Note: EPS may not be comparable

PDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of $0.15, $0.12 better than the analyst estimate of $0.03. Revenue for the quarter came in at $68 million versus the consensus estimate of $45.3 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
• Renasant Corp. (RNST) Tops Q1 EPS by 3c
• Baker Hughes Company (BKR) Tops Q1 EPS by 4c, Beats on Revenue